More recently, Liu et al.[50] showed that miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44, which establishes a strong rationale for developing miR-34a as a novel therapeutic agent against prostate cancer stem cells. Here, CD44 is linked to prostate carcinoma.